A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs MVI 118 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 24 Nov 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
- 31 Jul 2020 Results published in the Clinical Cancer Research